Cover Story
News Analysis
By Matthew Bin Han Ong
The Advanced Research Projects Agency for Health, the centerpiece of the Biden Administration’s war on disease, is designed to be something much more than an ordinary federal bureaucracy.
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Trump 2016: A look back at the 45th president’s impact on oncology
- A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Long-term risks from prostate cancer treatment detailed in new report